ArticleDiscover oncology2025
LRP11 as a potential predictor of poor prognosis and immune suppression in lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD), the predominant histologic subtype of non-small cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality worldwide. However, stable biomarkers that simultaneously reflect prognosis and the tumor immune microenvironment are lacking. Low-density lipoprotein receptor-related protein 11 (LRP11), a member of the LDL receptor family, has been implicated in various cancers, but its role in LUAD remains unexplored.
methodsIn this study, we systematically evaluated the expression, clinical associations, and prognostic value of LRP11 in LUAD using transcriptomic data from TCGA and GEO platforms. Immune cell infiltration was analyzed using CIBERSORT and ssGSEA. Co-expression and pathway enrichment analyses were performed to investigate the underlying mechanisms, and a prognostic nomogram incorporating LRP11 was constructed and validated. New experimental data included: Western blotting (WB) and qRT-PCR to compare LRP11 expression levels in BEAS-2B, A549, and H1915 cells; immunohistochemical (IHC) staining of paired tissues for LRP11 localization; and LRP11 knockdown in A549/H1915 cells using two siRNAs to assess cell viability (CCK-8), migration (scratch assay), invasion (Transwell assay), and clonogenic ability.
resultsLRP11 was stably overexpressed in LUAD and was significantly associated with advanced pathological stage, distant metastasis, and poor survival outcomes. The prognostic nomogram incorporating LRP11 significantly improved the prediction of 1-, 3-, and 5-year survival. Immune analysis revealed that high LRP11 expression was associated with a decrease in CD8⁺ T cells and dendritic cells, while Tregs and M2 macrophages were enriched, indicating an immunosuppressive microenvironment. Functional enrichment analyses suggested that LRP11 is involved in RNA processing and antigen presentation pathways. Experimental data showed that LRP11 protein and mRNA levels were significantly elevated in A549/H1915 cells and LUAD tissues. LRP11 knockdown suppressed cell viability, reduced wound healing and transmembrane invasion, and decreased colony formation.
conclusionLRP11 is upregulated in LUAD and is associated with immune suppression and poor prognosis. In vitro functional assays support its pro-tumorigenic role. LRP11 holds potential as both a prognostic and immune-related biomarker in LUAD, with promise as a therapeutic target, warranting further mechanistic studies and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.